Orally Administered Targeted Recombinant Beta-Lactamase Prevents Ampicillin-Induced Selective Pressure on the Gut Microbiota: a Novel Approach to Reducing Antimicrobial Resistance

Jaana Harmoinen, Silja Mentula, Matti Heikkilä, Michel van der Rest, Päivi J. Rajala‐Schultz, Curtis J. Donskey, Rafael Frías, Pertti Koski, Nina Wickstrand, Hannele Jousimies–Somer,

Antimicrobial Agents and Chemotherapy · 2003 · 49 citations · 21 references

DOIFull text

Open access

Concepts

Abstract

Antibiotics that are excreted into the intestinal tract promote antibiotic resistance by exerting selective pressure on the gut microbiota. Using a beagle dog model, we show that an orally administered targeted recombinant beta-lactamase enzyme eliminates the portion of parenteral ampicillin that is excreted into the small intestine, preventing ampicillin-induced changes to the fecal microbiota without affecting ampicillin levels in serum. In dogs receiving ampicillin, significant disruption of the fecal microbiota and the emergence of ampicillin-resistant Escherichia coli and TEM genes were observed, whereas in dogs treated with ampicillin in combination with an oral beta-lactamase, these did not occur. These results suggest a new strategy for reducing antimicrobial resistance in humans.

References

21